HeartWare International Inc (NASDAQ:HTWR) Director Stephen N. Oesterle purchased 1,000 shares of the stock in a transaction dated Monday, February 29th. The shares were acquired at an average cost of $32.17 per share, for a total transaction of $32,170.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $32,170. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of HeartWare International Inc (NASDAQ:HTWR) opened at 33.50 on Thursday. The firm’s 50-day moving average price is $34.23 and its 200-day moving average price is $49.07. The firm’s market capitalization is $580.42 million. HeartWare International Inc has a 12 month low of $25.02 and a 12 month high of $95.59.
HeartWare International (NASDAQ:HTWR) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.21. The business earned $68.10 million during the quarter, compared to analyst estimates of $67.87 million. HeartWare International’s quarterly revenue was down 7.0% compared to the same quarter last year. On average, equities analysts anticipate that HeartWare International Inc will post ($3.00) earnings per share for the current year.
A number of brokerages have recently commented on HTWR. Northland Securities reissued a “hold” rating and set a $45.00 price target on shares of HeartWare International in a report on Monday, January 4th. Zacks Investment Research lowered HeartWare International from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 30th. SunTrust started coverage on HeartWare International in a report on Tuesday, December 8th. They set a “buy” rating and a $80.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $70.00 target price on shares of HeartWare International in a report on Thursday, November 5th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $70.00 target price on shares of HeartWare International in a report on Sunday, November 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $59.67.
Other institutional investors have bought and sold shares of the company. California State Teachers Retirement System raised its position in HeartWare International by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 32,018 shares of the company’s stock worth $1,614,000 after buying an additional 500 shares in the last quarter. Nationwide Fund Advisors increased its stake in HeartWare International by 42.7% in the fourth quarter. Nationwide Fund Advisors now owns 21,594 shares of the company’s stock worth $1,088,000 after buying an additional 6,458 shares during the last quarter. Numeric Investors LLC increased its stake in HeartWare International by 118.2% in the fourth quarter. Numeric Investors LLC now owns 135,085 shares of the company’s stock worth $6,808,000 after buying an additional 73,185 shares during the last quarter. Janus Capital Management increased its stake in HeartWare International by 46.6% in the third quarter. Janus Capital Management now owns 1,003,675 shares of the company’s stock worth $52,502,000 after buying an additional 318,887 shares during the last quarter. Finally, Hudson Executive Capital LP purchased a new stake in HeartWare International during the fourth quarter worth $26,221,000.
Heartware International, Inc is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (NASDAQ:HTWR), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure.